Roche Breast Cancer Drug Delays Progression by Over Four Months

Roche Holding Ag’s experimental drug giredestrant reduced the risk of breast cancer worsening by almost two thirds in some patients with an advanced form of the disease.

Patients in the trial were given Roche’s oral medicine giredestrant, combined with the immunosuppressant everolimus. In a group of patients with a specific genetic mutation called ESR1, the drug helped patients live about 4.5 months longer without their cancer worsening or them dying.